A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis

2024-517896-19-00 Protocol PH-F8IL10INTRA-03/24 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 29 Sep 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol PH-F8IL10INTRA-03/24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 42
Countries 1
Sites 2

Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

Key facts

Sponsor
Philogen S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
29 Sep 2025 → ongoing
Decision date (initial)
2025-04-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

VersionLevelCodeTermSystem organ class
23.1 PT 10039073 Rheumatoid arthritis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Philogen S.p.A.

Sponsor organisation
Philogen S.p.A.
Address
Piazza La Lizza 7
City
Siena
Postcode
53100
Country
Italy

Scientific contact point

Organisation
Philogen S.p.A.
Contact name
Louis Pluss

Public contact point

Organisation
Philogen S.p.A.
Contact name
Louis Pluss

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 42 2
Rest of world 0

Investigational sites

Italy

2 sites · Ongoing, recruiting
Centro Ricerche Cliniche Di Verona S.r.l.
UOC Reumatologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
AUSL di Reggio Emilia IRCCS, Arcispedale Santa Maria Nuova di Reggio Emilia
Rheumatology, Viale Risorgimento, 80, Reggio Emilia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-09-29 2026-03-04

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-20 Italy Acceptable
2025-04-15
2025-04-22
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-07 Italy Acceptable
2025-12-03
2025-12-10